Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low-intermediate and high risk patients

Radiotherapy and Oncology

Volumn 101, Issue 3, 2011, Pages 454-459

  Valdagni, Riccardo ^a,b   Nahum, Alan E ^c   Magnani, Tiziana ^a   Italia, Corrado ^d   Lanceni, Angelo ^e   Montanaro, Paolo ^f   Rancati, Tiziana ^a   Avuzzi, Barbara ^a   Fiorino, Claudio ^g  

^a Scientific Director's Office   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d Radiation Oncology Radiotherapy   (Italy)

^e BUSTO ARSIZIO HOSPITAL   (Italy)

^f Medical Oncology   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

; Conformal radiotherapy; Hyperfractionation; Prostate cancer

Indexed keywords

ADULT; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RELAPSE FREE SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 81855202008     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.07.017     Document Type: Article

References (46)

1. G.A. Viani, E.J. Stefano, and S.L. Alfonso Higher than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controller trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
2. P. Diez, I.S. Vogelius, and S.M. Benzten A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer Int J Radiat Oncol Biol Phys 77 2010 1066 1071
3. J.F. Fowler, and M. Ritter A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma Int J Radiat Oncol Biol Phys 32 1995 521 529
4. J.D. Forman, M. Duclos, and F. Shamsa Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study Int J Radiat Oncol Biol Phys 34 1996 655 662
5. S.M. Bentzen, and M.C. Joiner The linear quadratic approach in clinical practice M.C. Joiner, A.J. van der Kogel, Basic clinical radiobiology 2009 Hodder Arnold London 120 134
6. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
7. D.J. Brenner, A.A. Martinez, and G.K. Edmundson Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
8. J.F. Fowler, R. Chappell, and M. Ritter Is α/β ratio for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
9. D.J. Brenner Toward optimal external-beam fractionation for prostate cancer Int J Radiat Oncol Biol Phys 48 2000 315 316
10. C.R. King, and J.F. Fowler A simple analytic derivation suggests that prostate cancer α/β ratio is low Int J Radiat Oncol Biol Phys 51 2001 213 214
11. W.D. D'Souza, and H.D. Thames Is the α/β ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51 2001 1 3
12. M. Ritter Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer Semin Radiat Oncol 18 2008 249 256
13. S.M. Bentzen, and M.A. Ritter The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol 76 2005 1 3
14. P. Nickers, J. Hermesse, and J.M. Deneufbourg Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 97 2010 462 466
15. E.E. Yeoh, R.J. Fraser, and R.E. McGowan Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial Int J Radiat Oncol Biol Phys 55 2003 943 955
16. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
17. J.E. Livsey, R.A. Cowan, and J.P. Wylie Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis Int J Radiat Oncol Biol Phys 57 2003 1254 1259
18. G. Arcangeli, B. Saracino, and M. Gomellini A phase III randomized trial of high-dose conventional vs hypofractionated Radiotherapy in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 75 2009 S79 S80
19. A. Pollack, T. Li, and M. Buyyounouski Hypofractionation for prostate cancer: interim results of a randomized trial Int J Radiat Oncol Biol Phys 75 2009 S81 S82
20. G. Soete, S. Arcangeli, and G. De Meerleer Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity Radiother Oncol 80 2006 78 81
21. F. Leborgne, and J. Fowler Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison Int J Radiat Oncol Biol Phys 74 2009 1441 1446
22. N. Di Muzio, C. Fiorino, and C. Cozzarini Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer Int J Radiat Oncol Biol Phys 74 2009 392 398
23. E.F. Miles, and R.W. Lee Hypofractionation for prostate cancer: a critical review Semin Radiat Oncol 18 2008 41 47
24. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
25. G.S. Higgins, D.B. McLaren, G.R. Kerr, T. Elliott, and G.C.W. Howard Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy Int J Radiat Oncol Biol Phys 65 2006 982 989
26. M. Baumann, T. Hölscher, and J. Denham Fractionation in prostate cancer - is it time after all? Radiother Oncol 96 2010 1 5
27. A.E. Nahum, B. Movsas, and E.M. Horwitz Incorporating clinical measurements of hypoxia into tumor local-control modeling of prostate cancer: implications for the α/β ratio Int J Radiat Oncol Biol Phys 57 2003 391 491
28. 2 study Cancer 89 2000 2018 2024
29. 2 predicts for biochemical failure in prostate cancer patients Urology 60 2002 634 639
30. D.J. Brenner Hypofractionation for prostate cancer radiotherapy - what are the issues? Int J Radiat Oncol Biol Phys 57 2003 912 914
31. J.Z. Wang, M. Guerrero, and X. Li How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55 2003 194 203
32. J.F. Fowler, M.A. Ritter, and R.J. Chappell What hypofractionation protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56 2003 1093 1104
33. W.R. Lee The ethics of hypofractionation for prostate cancer Int J Radiat Oncol Biol Phys 73 2009 969 970
34. Y. Liao, M. Joiner, Y. Huang, and J. Burmeister Hypofractionation: what does it mean for prostate cancer treatment? Int J Radiat Oncol Biol Phys 76 2010 260 268
35. R. Valdagni, C. Italia, and P. Montanaro Is the alpha-beta ratio of prostate cancer really low? A prospective non-randomized trial comparing standard and hyperfractionated conformal radiation therapy Radiother Oncol 75 2005 74 82
36. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, prostate cancer V.I. 2009. .
37. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement: guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
38. C. Proust-Lima, J.M.G. Taylor, and S.G. Williams Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts Int J Radiat Oncol Biol Phys 72 2008 782 791
39. C. Proust-Lima, J.M.G. Taylor, and S. Secher Confirmation of a low α/β ratio for prostate cancer treated by external radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics Int J Radiat Oncol Biol Phys 79 2011 195 201
40. M. Milosevic, R. Bristow, and C. Menard Hypoxia is associated with early biochemical failure after radiotherapy in patients with prostate cancer Int J Radiat Oncol Biol Phys 75 2009 S105
41. P.J. Hoskin, D.M. Carnell, and N.J. Taylor Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry: initial observations Int J Radiat Oncol Biol Phys 68 2007 1065 1071
42. A.X. Meng, F. Jalali, and A. Cuddihy Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells Radiother Oncol 76 2005 168 176
43. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localized prostate cancer and out come of radical treatment: a retrospective analysis of two randomized radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351
44. H. Thames, D. Kuban, and L. Levy Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995 Int J Radiat Oncol Biol Phys 57 2003 929 943
45. M.C. Abramowitz, T. Li, and M.K. Buyyounouski The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Cancer 112 2008 55 60
46. A.C. Paulino, L.S. Constine, and P. Rubin Normal tissue development, homeostasis, senescence and the sensitivity to radiation injury across the age spectrum Semin Radiat Oncol 20 2010 12 20